Department of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland.
Laboratory of Lymphatic and Cancer Bioengineering, Institute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
J Exp Med. 2014 Jun 2;211(6):1153-66. doi: 10.1084/jem.20132000. Epub 2014 May 19.
Dendritic cells (DCs), and more recently lymph node stromal cells (LNSCs), have been described to tolerize self-reactive CD8(+) T cells in LNs. Although LNSCs express MHCII, it is unknown whether they can also impact CD4(+) T cell functions. We show that the promoter IV (pIV) of class II transactivator (CIITA), the master regulator of MHCII expression, controls endogenous MHCII expression by LNSCs. Unexpectedly, LNSCs also acquire peptide-MHCII complexes from DCs and induce CD4(+) T cell dysfunction by presenting transferred complexes to naive CD4(+) T cells and preventing their proliferation and survival. Our data reveals a novel, alternative mechanism where LN-resident stromal cells tolerize CD4(+) T cells through the presentation of self-antigens via transferred peptide-MHCII complexes of DC origin.
树突状细胞 (DCs),以及最近的淋巴结基质细胞 (LNSCs),已被描述为在淋巴结中使自身反应性 CD8(+) T 细胞耐受。尽管 LNSCs 表达 MHCII,但尚不清楚它们是否也会影响 CD4(+) T 细胞的功能。我们表明,MHCII 表达的主调控因子 II 类转激活蛋白 (CIITA) 的启动子 IV (pIV) 控制 LNSCs 内源性 MHCII 的表达。出人意料的是,LNSCs 还从 DC 获得肽-MHCII 复合物,并通过将转移的复合物呈递给幼稚的 CD4(+) T 细胞来诱导 CD4(+) T 细胞功能障碍,从而阻止它们的增殖和存活。我们的数据揭示了一种新的替代机制,即 LN 驻留的基质细胞通过呈递源自 DC 的转移肽-MHCII 复合物来耐受 CD4(+) T 细胞。